Author Correction: Genome-wide association study identifies Sjögren’s risk loci with functional implications in immune and glandular cells

By sjmartinez • November 2, 2022

Khatri B, Tessneer KL, Rasmussen A, Aghakhanian F, Reksten TR, Adler A, Alevizos I, Anaya JM, Aqrawi LA, Baecklund E, Brun JG, Bucher SM, Eloranta ML, Engelke F, Forsblad-d'Elia H, Glenn SB, Hammenfors D, Imgenberg-Kreuz J, Jensen JL, Johnsen SJA, Jonsson MV, Kvarnström M, Kelly JA, Li H, Mandl T, Martín J, Nocturne G, Norheim KB, Palm Ø, Skarstein K, Stolarczyk AM, Taylor KE, Teruel M, Theander E, Venuturupalli S, Wallace DJ, Grundahl KM, Hefner KS, Radfar L, Lewis DM, Stone DU, Kaufman CE, Brennan MT, Guthridge JM, James JA, Scofield RH, Gaffney PM, Criswell LA, Jonsson R, Eriksson P, Bowman SJ, Omdal R, Rönnblom L, Warner B, Rischmueller M, Witte T, Farris AD, Mariette X, Alarcon-Riquelme ME; PRECISESADS Clinical Consortium, Shiboski CH; Sjögren’s International Collaborative Clinical Alliance (SICCA), Wahren-Herlenius M, Ng WF; UK Primary Sjögren’s Syndrome Registry, Sivils KL, Adrianto I, Nordmark G, Lessard CJ. Author Correction: Genome-wide association study identifies Sjögren's risk loci with functional implications in immune and glandular cells. Nat Commun. 2022 Oct 31;13(1):6519. doi: 10.1038/s41467-022-34311-8. Erratum for: Nat Commun. 2022 Jul 27;13(1):4287. PMID: 36316359; PMCID: PMC9622850.

Tags: Publications, Rheumatology

The Effect of Urban Heat Island Intensity on the Rate of Emergency Department Visits for Acute Myocardial Infarctions

Lilley B, Amubieya O, Ziaeian B. The Effect of Urban Heat Island Intensity on the Rate of Emergency Department Visits for Acute Myocardial Infarctions. Eur[...]

Impact of e-cigarettes and flavoured vapes on respiratory health: where are we now?

Omcikus M, Tashkin DP, Dimic-Janjic S, Barjaktarevic I. Impact of e-cigarettes and flavoured vapes on respiratory health: where are we now? Curr Opin Pulm Med.[...]

KEYLYNK-009: Pembrolizumab Plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer and Clinical Benefit From First-Line Pembrolizumab Plus Chemotherapy

Rugo HS, Cescon DW, Robson ME, Im SA, Dalenc F, Yañez Ruiz E, Reyes-Cosmelli F, Walshe JM, Im YH, Kulyk S, Dudnichenko O, Llinás-Quintero N,[...]